Osteoarthritis Therapeutics Market Synopsis

Osteoarthritis Therapeutics Market Size Was Valued at USD 8.59 Billion in 2023, and is Projected to Reach USD 15.55 Billion by 2032, Growing at a CAGR of  6.82% From 2024-2032.

Osteoarthritis is the management of pain, inflammation as well as the preservation of the joint function. Management strategies for patients with this condition are NSAIDs for pain, physiotherapy involving muscle strengthening, and improved flexibility, corticosteroid injections for inflammation, and changes such as weight loss and regular, low impact activities. In more serious cases, the surgical and non-surgical treatments – like joint replacement – can help patients regain their normal functioning again.

• Osteoarthritis therapeutics market has strong development potential in future for the continuously rising incidence of osteoarthritis, a joint disease which is more common in the elderly population. Due to the current increasing average age of the global population, the amount of people having osteoarthritis is also likely to increase, implying the need for efficient treatment solutions. The market is defined by the availability of diverse therapeutic services, such as non-pharmacological treatment, medications, and operations. NSAIDs continue to be the first-line pharmacological therapy, while DMOADs are emerging as promising treatment options because of their possible impact on the disease’s development.
• Hence, along with the conventional treatments in osteoarthritis, biologics and regenerative medicine have become quite novel in the present day. Such are new strategies aimed at tissue repair and regeneration, which seems to provide cure for those patients. Higher incidences of osteoarthritis and the [-] effect that it has on a patient’s quality of life are driving the need for patients and healthcare providers to seek out newer and better therapeutic options to manage the condition; this has created a research and development buzz within the market space. In addition, the increasing prevalence of obesity and related metabolic diseases, which are potential risk factors for osteoarthritis, is a criterion for market growth.
• Region wise, North America dominates the osteoarthritis therapeutics market because of the effectiveness of the health-care facilities, a significantly high health-care spending, and a growing trend towards the use of new treatments. The Asia-Pacific area is expected to demonstrate the highest growth rate because of increasing health consciousness, enhanced medical facilities, and a higher population of patients. A major notable trend within the market relates to competitive relations between players from strategic collaboration, mergers, and acquisitions as companies require to broaden their product ranges and improve market positions. The market will therefore continue growing and patients benefiting from treatment due to increased understanding of osteoarthritis and subsequent adoption of more tailored therapy.

Osteoarthritis Therapeutics Market Trend Analysis

Increasing Prevalence and Innovative Solutions

• Osteoarthritis is another key trend with the therapeutics market gaining from the growth in disease incidence, especially among individuals in the post-nности age bracket. So many people are living longer and many are now faced with arthritis, gout, or rheumatism and its effects on their joints, making it necessary to develop better treatment options. An ageing population is observed specifically in such areas as North America and Europe, where osteoarthritis ranks high on the list of musculoskeletal diseases. The effect of this state on the manifestations of pathology and their limitation of everyday functioning underlies the necessity to develop effective therapeutic approaches Determined by severe impairment of QoL, both clinicians and patients explore modern therapeutic options.
• To meet this demand, pharma companies are shifting their attention in developing new osteoarthritis therapy, and of particular importance are the DMOADs. DMOADs differ from conventional therapies, which work only to treat the signs and symptoms like pain and inflammation, of osteoarthritis but not the disease itself; they are developed to slow/stop or even reverse osteoarthritis. Moreover this shift into development of disease modifying therapies signifies the shift in healthcare towards more cost effective measures that address the quality of life of a patient. This market is bound to grow further because with more research being done, more treatment possibilities come to the surface and people become more aware and asking for osteoarthritis therapeutics.

Emphasis on Personalized Medicine and Combination Therapies

• One other peculiarities of the development in the Osteoarthritis Therapeutics Market is the tendency towards increased use of personalized therapy, and utilization of biosimilars. Rapid developments in biomolecular and clinical research technologies have begun to change the nature of the therapies by enabling patient-specific treatments. This customization enhances efficiency of cure because it considers individual characteristics that affect development of diseases and their reactions to treatment. Other biologicals such as monoclonal antibodies and stem cell therapies are gradually moving into the osteoarthritis market since they may address the root of the problem as opposed to just the symptom. Such a change in treatment approach may be considered as a great leap forward in approach to osteoarthritis treatment, which is shifting now towards more targeted and focused treatments.
• Other trends include incorporation of combination therapies that make use of medicines and non drug treatments. Prescribing drugs in conjunction with physical therapy, exercise and dietary practices, healthcare providers seek to at least improve the quality of life of the patients. This kind of strategy does not focus merely on fear of pain and inflammation, but also on joint activity and use which is revealed to be vital for the essential human actions. This combination of these different approaches can be justified as being more effective as it takes into account that treating osteoarthritis involves not only a disease but a person. A similar case is observed in the current trends in the treatment and management of osteoarthritis, meaning that the osteoarthritis therapeutics market is set for future development of new orientations focused on patient-oriented care.

Osteoarthritis Therapeutics Market Segment Analysis:

Osteoarthritis Therapeutics Market Segmented based on By Drug Type, By Anatomy, By Route of Administration, By Sales Channel and By End-use

By Drug Type , Viscosupplementation Agents segment is expected to dominate the market during the forecast period

• To the credit of viscosupplementation agents are, therapeutic products that are primarily used to make joint or synovial fluid replenishments for patients diagnosed with OA. This condition raises the friction, and terminates the ease of movement, which plays a big impact in the quality of life of the ones affected. The principal working component here is hyaluronic acid which is crucial in the acts of joint cushioning and flexibility. When administered under the skin of the affected joint, these agents may deliver substantial amounts of hyaluronic acid to the target location and afford substantial pain relief, improved joint functioning, and mobility. This intervention is effective for patient’s especially those that have not benefited from normal methods of pain control.
• Viscosupplementation in the clinical practice is used adjunctively with other forms of OA medication and management protocols. This medication can be taken, together with other medication like non steroidal anti- inflammatory drugs and physiotherapy to ensure the patient gets the best results. The integration of the different types of therapy also targets both mechanical and inflammatory sources of osteoarthritis pain likely to result in better pain management as well as functional status. Although research is under way to find better alternatives for OA treatment with reasonable efficacy and safety, viscosupplementation is still an effective procedure for many patients because it is less invasive than the other surgical procedures developed for joint care.

By End-use, Hospital Pharmacies segment held the largest share in 2023

• Inpatient pharmacies are critical facilities as part of the health system since people with osteoarthritis may need hospitalization or complex treatment regimens. These pharmacy outlets are in a position to deal with a complete range of items with special emphasis on chronic pain reliefs and joint support remedies. Corticosteroids and viscosupplementation agents are often administered to patients during their hospital stay because they produce almost instant effect on joint pain and inflammation. Such timely intervention is useful since it can help to optimize the levels of patient comfort as well as their experiences while undergoing treatment for the conditions since acutely relieving the symptoms of osteoarthritis is possible.
• Also, considerable is the function of analysing patients’ requirements, as well as medical histories, and providing accurate medication regimens for them, which the hospitals’ pharmacies perform. They have a great working relationship with other healthcare providers to track the patient outcomes, review the medications efficacy and determine the right dosage to be administered. They also explain patients’ probable treatments, their consequences, and the role of patient compliance in therapy, which is highly important in osteoarthritis treatment. Hospital pharmacy meets this need through professional and efficient pharmaceutical care and this greatly enhances the quality of life of the patients who have this chronic disease.

Osteoarthritis Therapeutics Market Regional Insights:

North America is Expected to Dominate the Market Over the Forecast period

• North America controls the osteoarthritis therapeutics market due to the increased osteoarthritis incidence in the region’s aging population. Older population is always on the rise and the same goes for osteoarthritis that puts a lot of burden on healthcare facilities. These include health care facilities with highly developed health care diagnostic and treatment provisions especially the United States and Canada. Presences of some significant market players are a beneficial factor that improves the market environment, as these companies allocate substantial amounts of money to research and development of new therapies. It is also an investment that results in the development of new therapies that signify to the healthcare providers and to the patient population the available treatments.
• Also, increasing focus on better disease management adds to the continuing growth of the osteoarthritis therap meticustics market in North America. The treatment has various forms of medical treatment like NSAIDS and DMOADs for patients with mild symptoms, whereas more severe patients require physical and surgical remedies. There has been also the growth in programs and associations that focus on increased schooling on better care for patients with osteoarthritis. As a result, the fact that North America has a strong health care system, and there are constant research activities and various treatment modalities in the region make North America a vital player in the global osteoarthritis therapeutics market.

Active Key Players in the Osteoarthritis Therapeutics Market

• Pfizer Inc. (U.S.)
• Abbvie Inc. (U.S.)
• Novartis AG (Switzerland)
• Amgen Inc. (U.S.)
• Boehringer Ingelheim International GmbH (Germany)
• Samsung Bioepis (South Korea)
• Merck & Co., Inc. (U.S.)
• Sun Pharmaceutical Industries Ltd. (India)
• Teva Pharmaceuticals Industries Ltd. (Israel)
• AstraZeneca PLC (U.K.)
• Zimmer Biomet (U.S.)
• Stryker Corporation (U.S.)
• Other Key Players

Chapter 1: Introduction
 1.1 Scope and Coverage

Chapter 2:Executive Summary

Chapter 3: Market Landscape
 3.1 Market Dynamics
  3.1.1 Drivers
  3.1.2 Restraints
  3.1.3 Opportunities
  3.1.4 Challenges
 3.2 Market Trend Analysis
 3.3 PESTLE Analysis
 3.4 Porter's Five Forces Analysis
 3.5 Industry Value Chain Analysis
 3.6 Ecosystem
 3.7 Regulatory Landscape
 3.8 Price Trend Analysis
 3.9 Patent Analysis
 3.10 Technology Evolution
 3.11 Investment Pockets
 3.12 Import-Export Analysis

Chapter 4: Osteoarthritis Therapeutics Market by Drug Type
 4.1 Osteoarthritis Therapeutics Market Snapshot and Growth Engine
 4.2 Osteoarthritis Therapeutics Market Overview
 4.3 Viscosupplementation Agents
  4.3.1 Introduction and Market Overview
  4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.3.3 Key Market Trends, Growth Factors and Opportunities
  4.3.4 Viscosupplementation Agents: Geographic Segmentation Analysis
 4.4 Nonsteroidal Anti-inflammatory Drugs
  4.4.1 Introduction and Market Overview
  4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.4.3 Key Market Trends, Growth Factors and Opportunities
  4.4.4 Nonsteroidal Anti-inflammatory Drugs: Geographic Segmentation Analysis
 4.5 Analgesics
  4.5.1 Introduction and Market Overview
  4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.5.3 Key Market Trends, Growth Factors and Opportunities
  4.5.4 Analgesics: Geographic Segmentation Analysis
 4.6 Corticosteroids
  4.6.1 Introduction and Market Overview
  4.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.6.3 Key Market Trends, Growth Factors and Opportunities
  4.6.4 Corticosteroids: Geographic Segmentation Analysis
 4.7 Others
  4.7.1 Introduction and Market Overview
  4.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.7.3 Key Market Trends, Growth Factors and Opportunities
  4.7.4 Others: Geographic Segmentation Analysis

Chapter 5: Osteoarthritis Therapeutics Market by Anatomy
 5.1 Osteoarthritis Therapeutics Market Snapshot and Growth Engine
 5.2 Osteoarthritis Therapeutics Market Overview
 5.3 Knee Osteoarthritis
  5.3.1 Introduction and Market Overview
  5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.3.3 Key Market Trends, Growth Factors and Opportunities
  5.3.4 Knee Osteoarthritis: Geographic Segmentation Analysis
 5.4 Hip Osteoarthritis
  5.4.1 Introduction and Market Overview
  5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.4.3 Key Market Trends, Growth Factors and Opportunities
  5.4.4 Hip Osteoarthritis: Geographic Segmentation Analysis
 5.5 Hand Osteoarthritis
  5.5.1 Introduction and Market Overview
  5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.5.3 Key Market Trends, Growth Factors and Opportunities
  5.5.4 Hand Osteoarthritis: Geographic Segmentation Analysis
 5.6 Others
  5.6.1 Introduction and Market Overview
  5.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.6.3 Key Market Trends, Growth Factors and Opportunities
  5.6.4 Others: Geographic Segmentation Analysis

Chapter 6: Osteoarthritis Therapeutics Market by Route of Administration
 6.1 Osteoarthritis Therapeutics Market Snapshot and Growth Engine
 6.2 Osteoarthritis Therapeutics Market Overview
 6.3 Parenteral Route
  6.3.1 Introduction and Market Overview
  6.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.3.3 Key Market Trends, Growth Factors and Opportunities
  6.3.4 Parenteral Route: Geographic Segmentation Analysis
 6.4 Topical Route
  6.4.1 Introduction and Market Overview
  6.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.4.3 Key Market Trends, Growth Factors and Opportunities
  6.4.4 Topical Route: Geographic Segmentation Analysis
 6.5 Oral Route
  6.5.1 Introduction and Market Overview
  6.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.5.3 Key Market Trends, Growth Factors and Opportunities
  6.5.4 Oral Route: Geographic Segmentation Analysis

Chapter 7: Osteoarthritis Therapeutics Market by Sales Channel
 7.1 Osteoarthritis Therapeutics Market Snapshot and Growth Engine
 7.2 Osteoarthritis Therapeutics Market Overview
 7.3 Prescription Drugs & Over-the-Counter Drugs
  7.3.1 Introduction and Market Overview
  7.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  7.3.3 Key Market Trends, Growth Factors and Opportunities
  7.3.4 Prescription Drugs & Over-the-Counter Drugs: Geographic Segmentation Analysis

Chapter 8: Osteoarthritis Therapeutics Market by End-use
 8.1 Osteoarthritis Therapeutics Market Snapshot and Growth Engine
 8.2 Osteoarthritis Therapeutics Market Overview
 8.3 Hospital Pharmacies
  8.3.1 Introduction and Market Overview
  8.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  8.3.3 Key Market Trends, Growth Factors and Opportunities
  8.3.4 Hospital Pharmacies: Geographic Segmentation Analysis
 8.4 Retail Pharmacies
  8.4.1 Introduction and Market Overview
  8.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  8.4.3 Key Market Trends, Growth Factors and Opportunities
  8.4.4 Retail Pharmacies: Geographic Segmentation Analysis
 8.5 Others
  8.5.1 Introduction and Market Overview
  8.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  8.5.3 Key Market Trends, Growth Factors and Opportunities
  8.5.4 Others: Geographic Segmentation Analysis

Chapter 9: Company Profiles and Competitive Analysis
 9.1 Competitive Landscape
  9.1.1 Competitive Benchmarking
  9.1.2 Osteoarthritis Therapeutics Market Share by Manufacturer (2023)
  9.1.3 Industry BCG Matrix
  9.1.4 Heat Map Analysis
  9.1.5 Mergers and Acquisitions
  
 9.2 PFIZER INC (U.S.)
  9.2.1 Company Overview
  9.2.2 Key Executives
  9.2.3 Company Snapshot
  9.2.4 Role of the Company in the Market
  9.2.5 Sustainability and Social Responsibility
  9.2.6 Operating Business Segments
  9.2.7 Product Portfolio
  9.2.8 Business Performance
  9.2.9 Key Strategic Moves and Recent Developments
  9.2.10 SWOT Analysis
 9.3 ABBVIE INC (U.S.)
 9.4 NOVARTIS AG (SWITZERLAND)
 9.5 AMGEN INC (U.S.)
 9.6 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (GERMANY)
 9.7 SAMSUNG BIOEPIS (SOUTH KOREA)
 9.8 MERCK & CO INC (U.S.)
 9.9 SUN PHARMACEUTICAL INDUSTRIES LTD (INDIA)
 9.10 TEVA PHARMACEUTICALS INDUSTRIES LTD (ISRAEL)
 9.11 ASTRAZENECA PLC (U.K.)
 9.12 ZIMMER BIOMET (U.S.)
 9.13 STRYKER CORPORATION (U.S.)
 9.14 OTHER ACTIVE PLAYERS

Chapter 10: Global Osteoarthritis Therapeutics Market By Region
 10.1 Overview
 10.2. North America Osteoarthritis Therapeutics Market
  10.2.1 Key Market Trends, Growth Factors and Opportunities
  10.2.2 Top Key Companies
  10.2.3 Historic and Forecasted Market Size by Segments
  10.2.4 Historic and Forecasted Market Size By Drug Type
  10.2.4.1 Viscosupplementation Agents
  10.2.4.2 Nonsteroidal Anti-inflammatory Drugs
  10.2.4.3 Analgesics
  10.2.4.4 Corticosteroids
  10.2.4.5 Others
  10.2.5 Historic and Forecasted Market Size By Anatomy
  10.2.5.1 Knee Osteoarthritis
  10.2.5.2 Hip Osteoarthritis
  10.2.5.3 Hand Osteoarthritis
  10.2.5.4 Others
  10.2.6 Historic and Forecasted Market Size By Route of Administration
  10.2.6.1 Parenteral Route
  10.2.6.2 Topical Route
  10.2.6.3 Oral Route
  10.2.7 Historic and Forecasted Market Size By Sales Channel
  10.2.7.1 Prescription Drugs & Over-the-Counter Drugs
  10.2.8 Historic and Forecasted Market Size By End-use
  10.2.8.1 Hospital Pharmacies
  10.2.8.2 Retail Pharmacies
  10.2.8.3 Others
  10.2.9 Historic and Forecast Market Size by Country
  10.2.9.1 US
  10.2.9.2 Canada
  10.2.9.3 Mexico
 10.3. Eastern Europe Osteoarthritis Therapeutics Market
  10.3.1 Key Market Trends, Growth Factors and Opportunities
  10.3.2 Top Key Companies
  10.3.3 Historic and Forecasted Market Size by Segments
  10.3.4 Historic and Forecasted Market Size By Drug Type
  10.3.4.1 Viscosupplementation Agents
  10.3.4.2 Nonsteroidal Anti-inflammatory Drugs
  10.3.4.3 Analgesics
  10.3.4.4 Corticosteroids
  10.3.4.5 Others
  10.3.5 Historic and Forecasted Market Size By Anatomy
  10.3.5.1 Knee Osteoarthritis
  10.3.5.2 Hip Osteoarthritis
  10.3.5.3 Hand Osteoarthritis
  10.3.5.4 Others
  10.3.6 Historic and Forecasted Market Size By Route of Administration
  10.3.6.1 Parenteral Route
  10.3.6.2 Topical Route
  10.3.6.3 Oral Route
  10.3.7 Historic and Forecasted Market Size By Sales Channel
  10.3.7.1 Prescription Drugs & Over-the-Counter Drugs
  10.3.8 Historic and Forecasted Market Size By End-use
  10.3.8.1 Hospital Pharmacies
  10.3.8.2 Retail Pharmacies
  10.3.8.3 Others
  10.3.9 Historic and Forecast Market Size by Country
  10.3.9.1 Bulgaria
  10.3.9.2 The Czech Republic
  10.3.9.3 Hungary
  10.3.9.4 Poland
  10.3.9.5 Romania
  10.3.9.6 Rest of Eastern Europe
 10.4. Western Europe Osteoarthritis Therapeutics Market
  10.4.1 Key Market Trends, Growth Factors and Opportunities
  10.4.2 Top Key Companies
  10.4.3 Historic and Forecasted Market Size by Segments
  10.4.4 Historic and Forecasted Market Size By Drug Type
  10.4.4.1 Viscosupplementation Agents
  10.4.4.2 Nonsteroidal Anti-inflammatory Drugs
  10.4.4.3 Analgesics
  10.4.4.4 Corticosteroids
  10.4.4.5 Others
  10.4.5 Historic and Forecasted Market Size By Anatomy
  10.4.5.1 Knee Osteoarthritis
  10.4.5.2 Hip Osteoarthritis
  10.4.5.3 Hand Osteoarthritis
  10.4.5.4 Others
  10.4.6 Historic and Forecasted Market Size By Route of Administration
  10.4.6.1 Parenteral Route
  10.4.6.2 Topical Route
  10.4.6.3 Oral Route
  10.4.7 Historic and Forecasted Market Size By Sales Channel
  10.4.7.1 Prescription Drugs & Over-the-Counter Drugs
  10.4.8 Historic and Forecasted Market Size By End-use
  10.4.8.1 Hospital Pharmacies
  10.4.8.2 Retail Pharmacies
  10.4.8.3 Others
  10.4.9 Historic and Forecast Market Size by Country
  10.4.9.1 Germany
  10.4.9.2 UK
  10.4.9.3 France
  10.4.9.4 Netherlands
  10.4.9.5 Italy
  10.4.9.6 Russia
  10.4.9.7 Spain
  10.4.9.8 Rest of Western Europe
 10.5. Asia Pacific Osteoarthritis Therapeutics Market
  10.5.1 Key Market Trends, Growth Factors and Opportunities
  10.5.2 Top Key Companies
  10.5.3 Historic and Forecasted Market Size by Segments
  10.5.4 Historic and Forecasted Market Size By Drug Type
  10.5.4.1 Viscosupplementation Agents
  10.5.4.2 Nonsteroidal Anti-inflammatory Drugs
  10.5.4.3 Analgesics
  10.5.4.4 Corticosteroids
  10.5.4.5 Others
  10.5.5 Historic and Forecasted Market Size By Anatomy
  10.5.5.1 Knee Osteoarthritis
  10.5.5.2 Hip Osteoarthritis
  10.5.5.3 Hand Osteoarthritis
  10.5.5.4 Others
  10.5.6 Historic and Forecasted Market Size By Route of Administration
  10.5.6.1 Parenteral Route
  10.5.6.2 Topical Route
  10.5.6.3 Oral Route
  10.5.7 Historic and Forecasted Market Size By Sales Channel
  10.5.7.1 Prescription Drugs & Over-the-Counter Drugs
  10.5.8 Historic and Forecasted Market Size By End-use
  10.5.8.1 Hospital Pharmacies
  10.5.8.2 Retail Pharmacies
  10.5.8.3 Others
  10.5.9 Historic and Forecast Market Size by Country
  10.5.9.1 China
  10.5.9.2 India
  10.5.9.3 Japan
  10.5.9.4 South Korea
  10.5.9.5 Malaysia
  10.5.9.6 Thailand
  10.5.9.7 Vietnam
  10.5.9.8 The Philippines
  10.5.9.9 Australia
  10.5.9.10 New Zealand
  10.5.9.11 Rest of APAC
 10.6. Middle East & Africa Osteoarthritis Therapeutics Market
  10.6.1 Key Market Trends, Growth Factors and Opportunities
  10.6.2 Top Key Companies
  10.6.3 Historic and Forecasted Market Size by Segments
  10.6.4 Historic and Forecasted Market Size By Drug Type
  10.6.4.1 Viscosupplementation Agents
  10.6.4.2 Nonsteroidal Anti-inflammatory Drugs
  10.6.4.3 Analgesics
  10.6.4.4 Corticosteroids
  10.6.4.5 Others
  10.6.5 Historic and Forecasted Market Size By Anatomy
  10.6.5.1 Knee Osteoarthritis
  10.6.5.2 Hip Osteoarthritis
  10.6.5.3 Hand Osteoarthritis
  10.6.5.4 Others
  10.6.6 Historic and Forecasted Market Size By Route of Administration
  10.6.6.1 Parenteral Route
  10.6.6.2 Topical Route
  10.6.6.3 Oral Route
  10.6.7 Historic and Forecasted Market Size By Sales Channel
  10.6.7.1 Prescription Drugs & Over-the-Counter Drugs
  10.6.8 Historic and Forecasted Market Size By End-use
  10.6.8.1 Hospital Pharmacies
  10.6.8.2 Retail Pharmacies
  10.6.8.3 Others
  10.6.9 Historic and Forecast Market Size by Country
  10.6.9.1 Turkey
  10.6.9.2 Bahrain
  10.6.9.3 Kuwait
  10.6.9.4 Saudi Arabia
  10.6.9.5 Qatar
  10.6.9.6 UAE
  10.6.9.7 Israel
  10.6.9.8 South Africa
 10.7. South America Osteoarthritis Therapeutics Market
  10.7.1 Key Market Trends, Growth Factors and Opportunities
  10.7.2 Top Key Companies
  10.7.3 Historic and Forecasted Market Size by Segments
  10.7.4 Historic and Forecasted Market Size By Drug Type
  10.7.4.1 Viscosupplementation Agents
  10.7.4.2 Nonsteroidal Anti-inflammatory Drugs
  10.7.4.3 Analgesics
  10.7.4.4 Corticosteroids
  10.7.4.5 Others
  10.7.5 Historic and Forecasted Market Size By Anatomy
  10.7.5.1 Knee Osteoarthritis
  10.7.5.2 Hip Osteoarthritis
  10.7.5.3 Hand Osteoarthritis
  10.7.5.4 Others
  10.7.6 Historic and Forecasted Market Size By Route of Administration
  10.7.6.1 Parenteral Route
  10.7.6.2 Topical Route
  10.7.6.3 Oral Route
  10.7.7 Historic and Forecasted Market Size By Sales Channel
  10.7.7.1 Prescription Drugs & Over-the-Counter Drugs
  10.7.8 Historic and Forecasted Market Size By End-use
  10.7.8.1 Hospital Pharmacies
  10.7.8.2 Retail Pharmacies
  10.7.8.3 Others
  10.7.9 Historic and Forecast Market Size by Country
  10.7.9.1 Brazil
  10.7.9.2 Argentina
  10.7.9.3 Rest of SA

Chapter 11 Analyst Viewpoint and Conclusion
11.1 Recommendations and Concluding Analysis
11.2 Potential Market Strategies

Chapter 12 Research Methodology
12.1 Research Process
12.2 Primary Research
12.3 Secondary Research